26,900 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Erste Asset Management GmbH

Erste Asset Management GmbH acquired a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 26,900 shares of the company's stock, valued at approximately $792,000.

A number of other large investors have also added to or reduced their stakes in the stock. MONECO Advisors LLC increased its holdings in shares of Denali Therapeutics by 4.6% in the 3rd quarter. MONECO Advisors LLC now owns 9,100 shares of the company's stock worth $265,000 after purchasing an additional 400 shares in the last quarter. Assetmark Inc. grew its holdings in shares of Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company's stock worth $111,000 after acquiring an additional 580 shares during the period. CWM LLC grew its holdings in shares of Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company's stock worth $63,000 after acquiring an additional 654 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock worth $152,000 after acquiring an additional 920 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Denali Therapeutics by 5.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company's stock worth $613,000 after acquiring an additional 1,372 shares during the period. Hedge funds and other institutional investors own 92.92% of the company's stock.

Denali Therapeutics Stock Performance

Denali Therapeutics stock traded down $0.19 during mid-day trading on Wednesday, reaching $23.70. 680,464 shares of the company were exchanged, compared to its average volume of 1,063,289. The business has a fifty day moving average of $27.07 and a 200 day moving average of $24.59. The firm has a market cap of $3.41 billion, a P/E ratio of -8.69 and a beta of 1.35. Denali Therapeutics Inc. has a 12-month low of $14.56 and a 12-month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the firm posted ($0.72) earnings per share. Sell-side analysts predict that Denali Therapeutics Inc. will post -2.69 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DNLI. Cantor Fitzgerald lowered Denali Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, October 7th. HC Wainwright reissued a "buy" rating and set a $90.00 price target on shares of Denali Therapeutics in a report on Thursday, November 7th. Raymond James reissued a "market perform" rating on shares of Denali Therapeutics in a report on Thursday, October 10th. JPMorgan Chase & Co. cut their price target on Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating for the company in a report on Friday, October 11th. Finally, Jefferies Financial Group boosted their price target on Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $38.90.

Insider Activity

In related news, insider Alexander O. Schuth sold 15,558 shares of Denali Therapeutics stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $29.91, for a total value of $465,339.78. Following the completion of the sale, the insider now owns 178,066 shares in the company, valued at approximately $5,325,954.06. This trade represents a 8.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Vicki L. Sato sold 1,020 shares of Denali Therapeutics stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the completion of the sale, the director now owns 111,056 shares of the company's stock, valued at $3,331,680. This trade represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 86,578 shares of company stock worth $2,474,440 in the last ninety days. Company insiders own 7.90% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.